title: Pharmacological modulation of blood-brain barrier increases permeability of doxorubicin into the rat brain.
abstract: Our group recently demonstrated in a rat model that pretreatment with morphine facilitates doxorubicin delivery to the brain in the absence of signs of increased acute systemic toxicity. Morphine and other drugs such as dexamethasone or ondansetron seem to inhibit MDR proteins localized on blood-brain barrier, neurons and glial cells increasing the access of doxorubicin to the brain by efflux transporters competition. We explored the feasibility of active modification of the blood-brain barrier protection, by using morphine dexamethasone or ondansetron pretreatment, to allow doxorubicin accumulation into the brain in a rodent model. Rats were pretreated with morphine (10 mg/kg, i.p.), dexamethasone (2 mg/kg, i.p.) or ondansetron (2 mg/kg, i.p.) before injection of doxorubicin (12 mg/kg, i.p.). Quantitative analysis of doxorubicin was performed by mass spectrometry. Acute hearth and kidney damage was analyzed by measuring doxorubicin accumulation, LDH activity and malondialdehyde plasma levels. The concentration of doxorubicin was significantly higher in all brain areas of rats pretreated with morphine (P < 0.001) or ondansetron (P < 0.05) than in control tissues. The concentration of doxorubicin was significantly higher in cerebral hemispheres and brainstem (P < 0.05) but not in cerebellum of rats pretreated with dexamethasone than in control tissues. Pretreatment with any of these drugs did not increase LDH activity or lipid peroxidation compared to controls. Our data suggest that morphine, dexamethasone or ondansetron pretreatment is able to allow doxorubicin penetration inside the brain by modulating the BBB. This effect is not associated with acute cardiac or renal toxicity. This finding might provide the rationale for clinical applications in the treatment of refractory brain tumors and pave the way to novel applications of active but currently inapplicable chemotherapeutic drugs.
authors: Department of Paediatric Medicine, Neuro-oncology Unit, Anna Meyer Children's University Hospital Florence, Italy.
authors: Iacopo
authors: I
authors: Sardi
authors: Giancarlo
authors: G
authors: la Marca
authors: Stefania
authors: S
authors: Cardellicchio
authors: Laura
authors: L
authors: Giunti
authors: Sabrina
authors: S
authors: Malvagia
authors: Lorenzo
authors: L
authors: Genitori
authors: Maura
authors: M
authors: Massimino
authors: Maurizio
authors: M
authors: de Martino
authors: Maria G
authors: MG
authors: Giovannini
keywords: Doxorubicin; MDR transporters; blood-brain barrier; dexamethasone; mass spectrometry; morphine; ondansetron; rodent model
references: Am J Physiol Cell Physiol. 2008 Aug;295(2):C440-50
references: 18524938
references: J Neurochem. 2004 Aug;90(3):526-36
references: 15255930
references: Neuron. 2008 Nov 6;60(3):430-40
references: 18995817
references: Anticancer Res. 2005 Nov-Dec;25(6B):3825-31
references: 16312042
references: Nat Rev Neurosci. 2011 Mar;12(3):169-82
references: 21331083
references: Anticancer Res. 1999 Mar-Apr;19(2A):941-50
references: 10368637
references: J Neurooncol. 2011 Sep;104(2):619-20
references: 21234643
references: Trends Pharmacol Sci. 2006 Jan;27(1):17-24
references: 16337012
references: N Engl J Med. 1998 Sep 24;339(13):900-5
references: 9744975
references: Prog Neurobiol. 2005 May;76(1):22-76
references: 16011870
references: Circulation. 2009 Jan 6;119(1):99-106
references: 19103993
references: Epilepsy Res. 2006 Mar;68(3):213-28
references: 16361082
references: J Clin Invest. 1996 Jun 1;97(11):2517-24
references: 8647944
references: Biochem Pharmacol. 1995 May 17;49(10):1541-4
references: 7763297
references: Neurobiol Dis. 2010 Jan;37(1):13-25
references: 19664713
references: Am J Clin Oncol. 2002 Feb;25(1):60-4
references: 11823699
references: Curr Opin Oncol. 2004 Nov;16(6):593-600
references: 15627023
references: Cell Death Differ. 2006 Jul;13(7):1238-41
references: 16456578
references: Curr Pharm Des. 2011;17(26):2793-802
references: 21827403
references: Int J Cancer. 1994 Sep 15;58(6):860-4
references: 7927879
references: J Pharm Pharmacol. 1996 Aug;48(8):774-81
references: 8887724
references: Int J Cancer. 2004 May 1;109(5):759-67
references: 14999786
references: Clin Pharmacol Ther. 1973 Jul-Aug;14(4):592-600
references: 4723268
references: Brain Res. 2005 Dec 7;1064(1-2):21-31
references: 16289483
references: Cancer Res. 2001 Jan 15;61(2):771-7
references: 11212281
references: J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6
references: 10480340
references: Cancer Chemother Pharmacol. 2011 Jun;67(6):1333-40
references: 20737150
references: Ann N Y Acad Sci. 2006 Aug;1074:198-224
references: 17105918
references: Anal Biochem. 1978 May;86(1):271-8
references: 655387